Specialty Vaccine Company PaxVax Expands Global Commercial Team

REDWOOD CITY, CALIF. – August 7, 2014 -- PaxVax, Inc., a specialty vaccine company focused on travel and biodefense, today announced the expansion of its global commercial team with the appointments of Jonathan Klock as Vice President of Sales and Marketing, North America; Jeremy Gowler as Vice President of Global Marketing; and five U.S. National Account Directors. They join the European and U.S.-based commercial teams who came to PaxVax in conjunction with the company’s acquisition of the oral typhoid vaccine Vivotif ® last month.


Cholera: Haiti 

  • 2010-12 - First outbreak in more than a century
  • More than 580,000+ sickened / 7,500+ dead

Anthrax: New York City

  • Sept. 2001 - FBI stated worst biological attack in U.S. history
  • 5 deaths / 17 sickened

H5N1: Indonesia

  • More than half of H5N1 worldwide deaths occur in Indonesia
  • 60% of Bird Flu (H5N1) cases since 2003 have resulted in death

HIV: Swaziland

  • 230,000 living with HIV in Swaziland, 26% of adults have HIV
  • Worldwide: 60M+ infected / 30M dead

Dengue: Rio de Janeiro

  • Rio de Janeiro reports a dengue epidemic: 50,000+ cases in the city
  • Leading cause of fever among travelers & tourists 

to Better the World

Innovative. Beneficial. Simple.

Our mission is to develop and commercialize innovative vaccines against infectious diseases in a socially responsible manner.

PaxVax: Better Vaccines to Better the World

Subscribe to PaxVax - Socially Responsible Vaccines RSS